Lack Of Priority? No ANDAs Approved Using Expedited Pathway In FY 2018
Executive Summary
US FDA also refused to receive many priority generic drug applications, suggesting the expedited pathway may not be working as intended quite yet.
You may also be interested in...
US FDA Sets Generic Approval Record, But Generic Sponsors Aren't Celebrating
FDA relates new record to its plan to increase access to affordable drugs, but Association for Accessible Medicines says approvals alone will not increase competition.
Will GDUFA III Curtail Priority Assessments?
US FDA's expedited pathway for generics seems to provide more benefits for amendments than for original ANDAs.
US FDA's Generics Program Reaches 'Steady State' Milestone
OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.